| [1] |
Bray,F.Global cancer transitions according to the human development index(2008－2030)：a population－based study.Lancet Oncol, 2012, 13(8): 790-801.
|
| [2] |
北京市肿瘤防治研究所.1995～2010年北京市恶性肿瘤发病报告.2012.
|
| [3] |
Fearon,ER,Vogelstein B.A genetic model for colorectal tumorigenesis.Cell, 1990, 61(5): 759-767.
|
| [4] |
Schreinemachers,DM,Everson RB.Aspirin use and lung, colon, and breast cancer incidence in a prospective study.Epidemiology, 1994, 5(2): 138-146.
|
| [5] |
Cook NR,Lee IM,Gaziano JM, et al.Low－dose aspirin in the primary prevention of cancer：the Women's Health Study：a randomized controlled trial.JAMA, 2005, 294(1): 47-55.
|
| [6] |
Benamouzig R,Deyra J,Martin A, et al.Daily soluble aspirin and prevention of colorectal adenoma recurrence：one－year results of the APACC trial.Gastroenterology, 2003, 125(2): 328-336.
|
| [7] |
Logan RF,Grainge MJ,Shepherd VC, et al.Aspirin and folic acid for the prevention of recurrent colorectal adenomas.Gastroenterology, 2008, 134(1): 29-38.
|
| [8] |
Sandler RS,Halabi S,Baron JA, et al.A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.N Engl J Med, 2003, 348(10): 883-890.
|
| [9] |
Cerdan FJ,Torres－Melero J,Martinez S, et al.Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.N Engl J Med, 1993, 328(18): 1313-1316.
|
| [10] |
Cruz－Correa M,Hylind LM,Romans KE, et al.Long－term treatment with sulindac in familial adenomatous polyposis：a prospective cohort study.Gastroenterology, 1991, 101(3): 635-639.
|
| [11] |
Steinbach G,Lynch PM,Phillips RK, et al.The effect of celecoxib, a cyclooxygenase－2 inhibitor, in familial adenomatous polyposis.N Engl J Med, 2000, 342(26): 1946-1952.
|
| [12] |
Burn J,Bishop DT,Mecklin JP, et al.Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome.N Engl J Med, 2008, 359(24): 2567-2578.
|
| [13] |
Chan AT,Giovannucci EL,Meyerhardt JA, et al.Long－term use of aspirin and nonsteroidal anti－inflammatory drugs and risk of colorectal cancer.JAMA, 2005, 294(8): 914-923.
|
| [14] |
Chan AT,Ogino S,Fuchs CS.Aspirin use and survival after diagnosis of colorectal cancer.JAMA, 2009, 302(6): 649-658.
|
| [15] |
Giovannucci E,Egan KM,Hunter DJ, et al.Aspirin and the risk of colorectal cancer in women.N Engl J Med, 1995, 333(10): 609-614.
|
| [16] |
Thun MJ,Namboodiri MM,EE C, et al.Aspirin use and risk of fatal cancer.Cancer Res, 1993, 53(6): 1322-1327.
|
| [17] |
Bousser MG,Amarenco P,Chamorro A, et al.Terutroban versus aspirin in patients with cerebral ischaemic events(PERFORM)：a randomised, double－blind, parallel－group trial.Lancet, 2011, 377(9782): 2013-2022.
|
| [18] |
Rothwell PM,Wilson M,Price JF, et al.Effect of daily aspirin on risk of cancer metastasis：a study of incident cancers during randomised controlled trials.Lancet, 2012, 379(9826): 1591-1601.
|
| [19] |
Lebeau,B.No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy.Results from a randomized clinical trial of 303 patients.The " Petites Cellules" Group.Cancer, 1993, 71(5): 1741-1745.
|
| [20] |
de Gramont A,de Gramont A,Chibaudel B, et al.From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer.Semin Oncol, 2011, 38(4): 521-532.
|
| [21] |
Chan AT,Tranah GJ,Giovannucci EL, et al.Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma.J Natl Cancer Inst, 2005, 97(6): 457-460.
|
| [22] |
Zell JA,Ziogas A,Bernstein L, et al.Nonsteroidal anti－inflammatory drugs：effects on mortality after colorectal cancer diagnosis.Cancer, 2009, 115(24): 5662-5671.
|
| [23] |
Coghill AE,Newcomb PA,Campbell PT, et al.Prediagnostic non－steroidal anti－inflammatory drug use and survival after diagnosis of colorectal cancer.Gut, 2011, 60(4): 491-498.
|
| [24] |
Bastiaannet E,Sampieri K,Dekkers OM, et al.Use of aspirin postdiagnosis improves survival for colon cancer patients.Br J Cancer, 2012, 106(9): 1564-1570.
|
| [25] |
Hamano T,Homma Y,Otsuki Y, et al.Inguinal lymph node metastases are recognized with high frequency in rectal adenocarcinoma invading the dentate line.The histological features at the invasive front may predict inguinal lymph node metastasis.Colorectal Dis, 2010, 12(10): 200-205.
|
| [26] |
Watanabe K,Saito N,Sugito M, et al.Predictive factors for pulmonary metastases after curative resection of rectal cancer without preoperative chemoradiotherapy.Dis Colon Rectum, 2011, 54(8): 989-998.
|
| [27] |
Maslekar S,Sharma A,Macdonald A, et al.Mesorectal grades predict recurrences after curative resection for rectal cancer.Dis Colon Rectum, 2007, 50(2): 168-175.
|
| [28] |
Yamauchi M,Lochhead P,Morikawa T, et al.Colorectal cancer：a tale of two sides or a continuum? Gut, 2012, 61(6): 794-797.
|
| [29] |
Wong JJ,Hawkins NJ,Ward RL, et al.Methylation of the 3p22 region encompassing MLH1 is representative of the CpG island methylator phenotype in colorectal cancer.Mod Pathol, 2011, 24(3): 396-411.
|
| [30] |
Ali R,Toh HC,Chia WK.The utility of aspirin in dukes C and high risk dukes B colorectal cancer－the ASCOLT study：study protocol for a randomized controlled trial.Trials, 2011, 12: 261.
|
| [31] |
Sample D,Wargovich M,Fischer SM, et al.A dose－finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2)levels as a biomarker.Cancer Epidemiol Biomarkers Prev, 2002, 11(3): 275-279.
|
| [32] |
Ruffin MT,Krishnan K,Rock CL, et al.Suppression of human colorectal mucosal prostaglandins：determining the lowest effective aspirin dose.J Natl Cancer Inst, 1997, 89(15): 1152-1160.
|
| [33] |
Baron JA,Cole BF,Sandler RS, et al.A randomized trial of aspirin to prevent colorectal adenomas.N Engl J Med, 2003, 348(10): 891-899.
|
| [34] |
Midgley RS,McConkey CC,Johnstone EC, et al.Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer：final results of the VICTOR trial.J Clin Oncol, 2010, 28(30): 4575-4580.
|
| [35] |
Ellenberg JH.Selection bias in observational and experimental studies.Stat Med, 1994, 13(5-7): 557-567.
|
| [36] |
Ogino S,Kirkner GJ,Nosho K, et al.Cyclooxygenase－2 expression is an independent predictor of poor prognosis in colon cancer.Clin Cancer Res, 2008, 14(24): 8221-8227.
|
| [37] |
Soumaoro LT,Uetake H,Higuchi T, et al.Cyclooxygenase－2 expression：a significant prognostic indicator for patients with colorectal cancer.Clin Cancer Res, 2004, 10(24): 8465-8471.
|
| [38] |
Chan AT,Ogino S,Fuchs CS.Aspirin and the risk of colorectal cancer in relation to the expression of COX－2.N Engl J Med, 2007, 356(21): 2131-2142.
|
| [39] |
McQuaid KR,Laine L.Systematic review and meta－analysis of adverse events of low－dose aspirin and clopidogrel in randomized controlled trials.Am J Med, 2006, 119(8): 624-638.
|
| [40] |
Holmes MD,Chen WY,Schnitt SJ, et al.COX－2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin.Breast Cancer Res Treat, 2011, 130(2): 657-662.
|
| [41] |
Derry S,Loke YK.Risk of gastrointestinal haemorrhage with long term use of aspirin：meta－analysis.BMJ, 2000, 321(7270): 1183-1187.
|
| [42] |
Liao X,Lochhead P,Nishihara R, et al.Aspirin use, tumor PIK3CA mutation, and colorectal－cancer survival.N Engl J Med, 2012, 367(17): 1596-1606.
|